Inventory Huddle #6
May 13, 2020

Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser.

During the call, please submit questions via the Skype window.
Both audio and visuals are available through the Skype Meeting Broadcast link and are accessible via any browser.
Remdesivir: EUA Background

• Food and Drug Administration granted remdesivir (RDV) an Emergency Use Authorization (EUA) on May 1\textsuperscript{st} to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.

• U.S. Federal Government (HHS) is directing the distribution by determining how much drug each state will receive – retail and specialty pharmacies are not eligible.
  ✓ Gilead and AmerisourceBergen are not deciding which hospitals will receive remdesivir.

• Candidates for the donated doses must be patients on ventilators or on extracorporeal membrane oxygenation or who require supplemental oxygen due to room-air blood oxygen levels at or below 94 percent.
State Allocation Process

• State health departments will distribute the doses to appropriate hospitals in their states because state and local health departments have the greatest insight into community-level needs in the COVID-19 response.

• Healthcare providers interested in administering the donated experimental drug should contact their state health department.

• HHS expects RDV to be delivered to all 50 states as well as territories and the Veterans Health Administration and the Indian Health Service for distribution within those health systems.*

• Neither Gilead nor AmerisourceBergen are deciding which hospitals will receive RDV.

• Please note - AmerisourceBergen does not have visibility to the allocation plans at a state level.

* Source: HHS Press Release, 5/9/2020
Remdesivir – AmerisourceBergen Resources


- National Remdesivir Donation Inquiry Line: 1-877-987-4987
  - Do not contact Customer CARE with remdesivir questions (use dedicated resources)

- Dedicated e-mail box for inquiries on eligibility & designation for donation: remdesivir@amerisourcebergen.com
In addition to the donated doses for hospitalized patients in the United States and other countries, remdesivir also is available in the U.S. through clinical trials.

For information on clinical trials that are testing the use of remdesivir in COVID-19, visit www.clinicaltrials.gov.

For additional medical information about remdesivir, please visit www.askgileadmedical.com/remdesivir or call 1-866-MEDI-GSI (1-866-633-4474) Monday – Friday, 6am – 4pm PT.
PPE Availability

- AmerisourceBergen is working with suppliers to source N95 masks as production begins to ramp up overseas and domestically.

- At this time, we have begun to receive product into our distribution centers. We expect to have very limited inventory but will continue to stock as possible and on an ongoing basis.

- AmerisourceBergen will sell any PPE acquired at a fair price as acquired by our vendors—as always, our pricing is reflective of our own acquisition costs.

- In general, while AmerisourceBergen does stock some PPE, we are largely pharmaceutical focused. Our distribution centers are not designed to support large, bulky PPE items, so we will continue to focus our efforts on stocking N95 masks.
COVID-19 Test Kits

- AmerisourceBergen has been working to source antibody (serology) COVID-19 test kits for our customers. The FDA has issued Emergency Use Authorization (EUA) for some serology tests, however, others are being marketed without EUA or other FDA approval.
  - New FDA requirements for manufacturers to submit data.
- The quality, efficacy and accuracy of currently marketed test kits varies greatly, and the sourcing has been challenging. AmerisourceBergen does not have confidence in the quality of serology test kits that have been offered to us.
- As a result, we’ve made the decision not to distribute COVID-19 serology tests at this time.
- Near-term efforts will focus on continuously monitoring the market for reliable test offerings, helping prepare and educate our customers and staying up-to-date on our customers’ needs.
AmerisourceBergen Business Continuity Update

- Health screening questionnaire and temperature testing at all sites across the U.S. now active

- Policy across our distribution network for how to handle any confirmed COVID-19 cases within our associate population, including associate guidance, deep sanitation, and mitigation steps

- Decision on Olive Branch distribution center
  - Protected associates by allowing them to monitor their own health so they can return to work healthy and ready to continue to support your patients
  - During the temporary closure, customers normally serviced by the Olive Branch DC are being serviced by an alternative DC

- Leveraging best practices and lessons learned from successful Newburgh, NY temporary closure (April 6) and reopening
FEEDBACK

We want to hear how AmerisourceBergen is doing to support you during the COVID-19 crisis. Share your feedback via a 2-minute survey.


Most recent FAQs also available there.
We are united in our responsibility to create healthier futures.
Q & A

Please submit questions directly in the Skype window